CompletedNot Applicable

Sevelamer Hydrochloride in Peritoneal Dialysis Patients

Hong Kong60 participantsStarted 2008-07

Plain-language summary

To test the hypothesis that second-line fixed low-dose sevelamer hydrochloride therapy is as effective as first-line high-dose sevelamer hydrochloride therapy in limiting the progression of cardiovascular calcification.

Who can participate

Age range25 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * ESRD patients receiving long-term peritoneal dialysis treatment with hyperphosphatemia currently receiving aluminum-based phosphorus binders or whose phosphorus control remains suboptimal with calcium-based binders only * Patients who cannot afford to self-pay sevelamer hydrochloride. * Patients who provided informed consent for the study Exclusion Criteria: * Patients with underlying active malignancy * Patients with cyanotic congenital heart disease * Patients with poor general condition * Patients with plan for living related kidney transplant within coming 1 year * Female patients with pregnancy

What they're measuring

Changes in coronary artery, aortic valve, mitral annulus calcium scores

Timeframe: over 24 months

Trial details

NCT IDNCT00745589

SponsorThe University of Hong Kong

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2014-10

View on ClinicalTrials.gov More Endstage Renal Disease trials